, selenocyanates [15] [16] [17] , selenoureas 18, 19 and selenoesters [20] [21] can be highlighted. The reported mechanisms of action for these compounds vary greatly: reduction of oxidative stress 22 , induction of mutations 23 , angiogenesis inhibition 16, 24 , apoptosis induction 25 and reversal of multidrug resistance (MDR) 25 . Interestingly, selenium and Se-containing compounds are like a double-edged sword 26 : they can exert an antioxidant action that prevents cancer in normal cells [1] [2] [3] 22, 26 , whereas they can act in cancer cells as pro-oxidants that generate reactive oxygen species (ROS). These Se-induced ROS can then trigger apoptotic processes 25, 26 and can induce mutations in DNA, as well as DNA breaks 23, 26 .
The multidrug resistance of cancers and bacterial infections is an increasing and troublesome problem nowadays, due to the appearance of resistant cancers and resistant bacterial strains [27] [28] . It has been observed that one of the most common mechanisms of cancer MDR is the over-expression of the efflux pumps 29 , which are membrane proteins that can recognise and extrude out of the cells toxic agents such as the anticancer drugs 29, 30 . In this context, different studies 6, 7, [14] [15] [16] [31] [32] [33] pointed out that selenocompounds can enhance the activity of the drugs used in cancer chemotherapy in a synergic way if they are applied together. Some examples of studies that have shown this synergistic enhancement of the chemotherapy drugs action are: (i) sodium selenite potentiates the cytotoxicity of imatinib in HCT116 colorectal cancer cells 6 ; (ii) sodium selenite enhances the cytotoxicity of cisplatin in MCF-7 breast carcinoma cells 7 ; (iii) the cytotoxicity of paclitaxel is augmented in presence of methylseleninic acid in MDA-MB-231 breast adenocarcinoma cells 14 ; (iv) the combined treatment of mice with diphenylmethyl selenocyanate and cisplatin decreases the size of induced tumours 15 ; (v) a complex organoselenocyanate inhibited the angiogenesis and enhanced the therapeutic efficacy of cyclophosphamide in tumour bearing Swiss albino mice 16 ; (vi) selenocystine can potentiate the capacity of auronafin to induce apoptosis in A549 lung cancer cell line 31 , (vii) selenocystine also enhances the therapeutic effect of doxorubicin in liver carcinoma HepG2 cell line 32 ; and (viii) Se-methylselenocysteine increases the antitumour activity of different chemotherapeutic agents in vivo (cisplatin, cyclophosphamide, oxaliplatin and irinotecan) in mice 33 .
Taking in mind the aforesaid antecedents, and seeking to determine the influence of selenocompounds on multidrug resistance, we evaluated the capacity of a cyclic selenoanhydride and ten selenoesters 20, 21 to inhibit a MDR efflux pump such as the
A R T I C L E I N F O A B S T R A C T
ABCB1 (ATP Binding Cassette Subfamily B Member 1) protein in MDR mouse T-lymphoma cells as shown previously 25 ; as well as their capacity to trigger apoptotic events in these mouse Tlymphoma cells 25 . Results showed a noteworthy and promising activity, as the four most active compounds (1, 9-11, Figure 1 ) exerted a (1.7-3.6)-fold stronger efflux pump inhibitory activity than the reference verapamil at concentration 10-fold lower. In addition, those four most active selenium derivatives triggered apoptotic events in more than the 80% of the gated cells 25 .
Herein we have evaluated these selenocarbonyl derivatives 1-11 (Table 1) in a human MDR cell line of colon adenocarcinoma: the Colo 320/MDR-LRP cell line resistant to doxorubicin over-expressing ABCB1 (MDR1)-LRP 27, 34 . The aim of our study is to compare the MDR reversing and efflux pump inhibiting properties of selenocompounds 1-11 in human cancer cell lines with the previous results in mouse cells 25 , as well as to evaluate their cytotoxicity in normal cells to determine their selectivity. For comparison, four additional compounds have been chosen as references to estimate the role of the presence of a selenium atom ( Table 1) . On one hand, the phthalic anhydride (12) In this study we evaluate a series of the selenocompounds previously reported 20, 21 that showed activity 25 as novel efflux pump inhibitors in parental L5178Y mouse T-lymphoma cells and in its MDR subline that expresses the ABCB1 protein after being transfected with the human ABCB1 gene 35 . Thus, the selenocarbonyl compounds 1-11, shown in Table 1 , have been examined in different biological studies at the ABCB1-overexpressing Colo 320/MDR-LRP resistant cell line, as well as the equivalent sensitive cell line (Colo 205 doxorubicin sensitive cells), following previously described methodologies 25, 27, [34] [35] [36] [37] [38] . The selected derivatives 1-11 included the selenoanhydride 1 and the selenoesters 2-11, whose alkyl moiety contains different functional groups: a methyl group in 2-5, a methylcarbamoil group in 6, a methyloxycarbonylmethyl group in 7, a phenyloxycarbonylmethyl group in 8 and different ketonecontaining alkyl groups in 9-11. The selenocompounds 1-11 were synthesized according to the methods described earlier 20, 21 .
The following biological evaluations were considered in this study: the assessment of their cytotoxicity, the inhibition of ABCB1 protein, and the ability of the compounds to induce apoptotic events. These biological activities were determined using rhodamine 123 accumulation assay, MTT method and flow cytometry measurements. Besides, the selectivity of the compounds towards cancer cells compared to normal cells was evaluated using the non tumoral MRC-5 human embryonic lung fibroblast cell line, as described previously 39 . The different selectivity indexes (SI) were calculated as the quotient of the IC 50 value in the non-tumoral cells divided by the IC 50 in the MDR cancer cell line. The compounds activity towards cancer cells is considered as strongly selective if the selectivity index (SI) value is higher than 6, moderately selective if 3 < SI < 6, slightly selective if 1 < SI < 3 and non-selective if SI is lower than 1 40 . Previously reported studies [41] [42] [43] have evaluated the selectivity of novel antiproliferative and cytotoxic agents towards colon/colorectal cancer cells using human 41 or murine [42] [43] fibroblasts as non-tumoral cell lines. Among them, Meker et al. The rhodamine 123 accumulation assay 25, [34] [35] [36] [37] was selected to determine the capacity of compounds 1-11 to inhibit the extrusion of the dye (an ABCB1 substrate) out of the MDR Colo 320 cancer cells. Verapamil was chosen as positive control. To determine the activity of these derivatives, the fluorescence intensity emitted by the treated cells was measured and the mean for the treated cells was calculated and compared with the untreated cells. Results were given in terms of the fluorescence activity ratio (FAR), as indicated in equation (1) . Once the FAR values were determined, they are divided by the FAR of verapamil, as showed in equation (2), to calculate the FAR quotient. The values determined for the compounds evaluated are provided in Table 2 . Additionally, Figure 2 compares the activity of the most potent inhibitors in colon adenocarcinoma cells with that in MDR-derived mouse T-lymphoma cell line 25 .
Figure 2. FAR quotient values, expressed in terms of percentages
in respect to verapamil tested at 10-fold higher concentration (activity of verapamil = 100%), calculated for the most active compounds (1, 9-11) in MDR mouse T-lymphoma cell line 25 and in MDR Colo 320 cells.
According to the results obtained, the most active compounds (1 and 9-11) showed a strong efflux pump inhibition: (1.3-4.0)-fold higher compared to verapamil at a concentration 10 times lower. The inhibiting activity of selenoanhydride 1 was 4.32-fold stronger than that of verapamil when tested at the same 20 μM concentration (9-11 were not tested at 20 μM as they had IC 50 values more than 10 times lower than this concentration). The ABCB1 inhibition measured at 2 μM concentration for the active compounds (1 and 9-11) in MDR Colo 320 cells indicated a significant increase of the inhibiting activity of 9-11 in comparison to that described for the ABCB1-transfected mouse T-lymphoma cells 25 . As shown in Figure 2 , the highest improvement was found in the case of derivatives 10 and 11, where the inhibition compared to verapamil, raised from 34% to 217% and from 46% to 228%, respectively. On the other hand, derivatives 2-7 exerted a low modulating action on the ABCB1 efflux pump, as their pump inhibitory action varied from 18% to 28% of the inhibitory action exerted by the reference verapamil. In addition the phenoxycarbonyl selenoester 8 showed a significant inhibition of the efflux pump (68.1% of verapamil activity at the same concentration -20 μM).
In accordance to the results obtained for MDR mouse Tlymphoma cells, these results show that the four derivatives with potent efflux pump inhibitory activity are the cyclic selenoanhydride 1, and the ketone selenoesters (9-11). The selenoesters with secondary non-ketone functional groups (ester, amide, or a methyl group) have a weaker MDR reversing activity, both in MDR colon adenocarcinoma and in MDR mouse T-lymphoma MDR cells. This fact suggests that the influence of the selenocarbonyl moiety (selenoanhydride, selenoester) and of the secondary carbonyl functional group present in the alkyl moiety bound to selenium in the selenoesters seems to be more relevant for the efflux pump inhibition than the different substituents at the aromatic moiety bound to the carbonyl group of the selenoesters evaluated. As proposed earlier 20, 25 , the
observed changes of the activity with the functional group can be explained both by the polarity modulation and by the modification of the selenoester hydrolysis exerted by the functional group present in the alkyl moiety bound to the selenium atom. These modifications in the substituents placed at the opposite side of the molecule may exert a minor influence over the selenoester, as these substituents are placed at a higher distance of the selenium atom than the functional groups of the alkyl moiety. Considering the data obtained at 2 μM concentration for the efflux pump inhibition using rhodamine 123 retention assay in Colo 320 cells, the most active compound is the methylketone selenoester 9, with a 2-fold stronger efflux pump inhibitory activity than the two tert-butylketone selenoesters 10 and 11 and with a 3-fold stronger ABCB1 inhibiting effect than that of the selenoanhydride 1. Among the tert-butylketones, there were no significant differences in the activity when the 3,5-dimethoxyphenyl moiety of 11 was replaced by the 4-chlorophenyl one of 10. In MDR mouse Tlymphoma cells 25 , 9 is also the most active compound at 2 μM with a 2-fold higher activity than 1, but in this case 10 and 11 showed a much lower inhibition activity (Figure 2) .
Interestingly, the replacement of the Se atom of 1 with an oxygen atom (12) practically eliminated the capacity of 1 to inhibit the ABCB1 efflux pump. The FAR quotient of 12 was much lower than that of 1 at the two concentrations assayed, and even 27-fold lower at the 20 μM concentration. A lack of the efflux pump inhibitory properties can be observed for the three inorganic chalcogen cyanates 13-15, as well. All reference compounds (12-15) displayed a very weak ABCB-1 inhibition (FAR quotient <20), in the range of DMSO, incomparably lower than the active selenoesters 9-11. Although the comparison of results for 1 and 12 underlines a crucial and irreplaceable role of Selenium within the cyclic anhydrides, results for three cyanates 13-15 indicate that not only presence but a particular location and the type of bonding are responsible for the efflux pump inhibitory properties. Hence, the endocyclic position of Se in the vicinity of carbonyl groups seems to be very profitable whereas the CNneighborhood and significant alkaline properties are unfavorable regardless of the chalcogen atom (Se, O or S). These results additionally confirmed the inference about the beneficial role of the ketone group within Se-compounds for the ABCB-1 inhibitory properties, coming from the studies on compounds 1-11 in both T-Lymphoma and Colo-cancer cells.
The cytotoxicity exerted by the selenocarbonyl compounds 1-11 in both the sensitive and resistant Colo cells was measured using MTT method, and results were given in terms of IC 50 values ( Table 3 ). The three most active derivatives (9-11) had IC 50 values in nanomolar range in MDR Colo 320 cells. Compound 11 was the most potent one with an IC 50 of 350 nM. In the sensitive cell line, these three compounds showed IC 50 values in the range from 1.19 to 5.48 μM. None of the remaining derivatives 1-8 were cytotoxic in the sensitive Colo 205 cell line at concentrations lower than the selected threshold (100 μM); and only 1 and 4 showed IC 50 values below 100 μM against MDR Colo 320 cells. At the sight of the results, the ABCB1 efflux pump inhibitory activity of the selenoanhydride 1 is truly interesting for possible future applications in medicine: 1 exerts a 1.35-fold and a 4.32-fold stronger pump inhibition than verapamil at concentrations 32 times and 3.2 times lower, respectively, than the IC 50 value determined for 1 in this resistant cell line. Interestingly, all the derivatives were more cytotoxic against the resistant Colo 320/MDR cell line than against the sensitive Colo 205 cells. The ketone selenoester 9 was the most selective compound against the MDR cell line, with a selectivity index (SI) of 10 to the MDR cells in respect to the sensitive cells. 
With the exception of derivatives 1 and 8, all compounds showed IC 50 values below 100 μM in the non-tumoral human MRC-5 lung fibroblast cell line. Among them, the IC 50 values of compounds 3, and 5-7 were from 17 to 77 μM, whereas the IC 50 values of derivatives 2 and 9-11 placed in the 4-8 μM range. It is noteworthy that the five most potent ABCB1 efflux pump inhibitors (1, 8-11 ) exert a selective action towards the colon adenocarcinoma cells compared to the MRC-5 cells, especially against the MDR cell line: 1 and 8 were slightly selective towards Colo 320 cells, and 9-11 showed a strong selectivity towards the resistant cells (the most selective, 11, had a SI = 14.4). Among them, 10 and 11 were moderately selective towards the sensitive Colo 205 cell line. In contrast, the remaining selenocompounds (2-7) were non-selective, with the exception of 4 on Colo 320 MDR cells (SI = 2.3, slightly selective). None of the four reference compounds evaluated (12) (13) (14) (15) showed cytotoxic activity in any of the cell lines assayed: the human colon adenocarcinoma cells (Colo 205 and Colo 320, Table 3 ), the non-tumoral MRC-5 cells (Table 3 ) and the mouse T-lymphoma cells (PAR and MDR, data now shown). In the case of the pair selenoanhydride (1) -phthalic anhydride (12), results highlight the importance of the selenium atom to the biological activity.
Regarding the SAR in the cytotoxicity assay, only the ketone selenoesters 9-11 showed IC 50 values below 10 μM in both colon adenocarcinoma cell lines. The tert-butylketone selenoesters were more cytotoxic than the methylketone one in sensitive Colo 205 cells. In the resistant Colo 320 cells, with the equivalent aromatic substituent (4-chlorophenyl), the methyl ketone selenoester 9 was 2-fold more cytotoxic than the tert-butylketone 10. In addition, the change of the aromatic moiety from the 4-chlorophenyl (10) to the 3,5-dimethoxyphenyl (11) moiety improved the cytotoxicity and converted 11 into the most cytotoxic selenocompound. In contrast, the selenoanhydride 1 was not cytotoxic at concentrations below 100 μM in sensitive cells, and was less active (63.9 μM) than 9-11 in resistant cells.
The SAR analysis for the selectivity towards the cancer cells compared to MRC-5 non-tumour cell line is in analogy with that one observed for the cytotoxicity in resistant Colo 320 cells. In this case, 11 is the most selective compound. The ability of the compounds to trigger the different apoptotic processes in resistant Colo 320 cells was determined using flow cytometry. Selenocompounds 1-11 were evaluated at a 2 μM concentration, and the apoptotic derivative M627 (12H-benzo[α]phenothiazine) 38 was tested as positive control at a 20 μM concentration. Results are provided in Table 4 and the pro-apoptotic activity of the most active derivatives (1, 9-11) in MDR-derived mouse T-lymphoma cells 25 and in the resistant Colo 320 human cell line are compared in Figure 3 . Like in MDR mouse T-lymphoma cells 25 , the selenoanhydride 1 and the ketone selenoesters 9-11 showed a strong capacity to trigger apoptotic events in resistant colon adenocarcinoma cells. These active derivatives induced apoptosis (including early and late apoptosis, and necrosis) in 64-72 % of the gated cells, almost in the same range than the positive control (80.5 %) but at a 10-fold lower concentration, reaching in this way an 80-90 % of the action of the positive control M627 at a 10-fold lower concentration. As shown in Figure 3 , derivatives 10 and 11 were clearly stronger apoptosis inducers in colon cells than in Tlymphoma cells, whereas the M627, 1 and 9 were slightly more pro-apoptotic in mouse MDR T-lymphoma cell line. The remaining selenoesters 2-8 were moderate apoptosis inducers, as they triggered apoptotic events in 24-35 % of cells at a 10-fold lower concentration than that of the positive control. Among these derivatives, only the selenoesters 7-8 could induce apoptotic events in more than one third of the gated cells. Both contain a carboxylic ester in the alkyl moiety bound to the selenium atom. Finally, the four references 12-15 had no capacity to induce apoptotic events in Colo 320 cells as they have apoptotic quotients close to negative controls, and as all the selenocompounds 1-11 induce apoptotic events in a significantly higher percentage than the reference compounds 12-15. In the SAR analysis of the apoptosis induction assays, it is noteworthy that the selenoanhydride 1 and the active ketone selenoesters 9-11 exerted differential apoptotic actions: in the case of the selenoanhydride 1 the early apoptotic processes were triggered in the 66.1 % of cells and weakly the late apoptotic/necrotic events (5.1 % of cells). On the other hand, the ketone derivatives 9-11 were more potent inducers of late apoptosis and necrotic processes (35-42 % of cells) than of early apoptosis (28-30 % of cells). Both the selenoanhydride 1 and the ketone selenoesters 9-11 were stronger inducers of the early apoptosis and of the late apoptosis/necrosis, respectively, than the positive control M627. Among the ketone selenoesters, the methylketone selenoester 9 was more pro-apoptotic than the tertbutylketone selenoester (10) with the same aromatic substituent. But replacing the 4-chlorophenyl substituent of 10 with the 3,5-dimethoxyphenyl moiety of 11 augments the apoptotic potency to convert the compound 11 into the most pro-apoptotic one.
To conclude, this study in human colonic adenocarcinoma cell lines confirms the results previously obtained in MDR mouse Tlymphoma cells 25 . Among the 11 selenocompounds evaluated, the selenoanhydride 1 and the ketone selenoesters 9-11 have showed a very interesting activity in the different biological assays performed. According to the results presented herein, these four active derivatives are more potent inhibitors of the ABCB1 efflux pump than the reference verapamil and also excellent apoptosis inducers. In addition, the three ketone selenoesters 9-11 are potent and strongly selective cytotoxic agents, as they showed IC 50 values in nanomolar range at the resistant Colo 320 cells whereas their IC 50 increased to the micromolar range in the non-tumour MRC-5 cell line. In addition, the replacement of the selenium atom of the selenoanhydride 1 by oxygen (12) eliminates the aforesaid interesting activities shown by 1. In the case of the inorganic chalcogen compounds 13-15, none of them showed activity regarding the efflux pump inhibition, cytotoxicity or apoptosis induction. The results for selenoanhydride 1 and selenoesters 2-11 together with those for the additional compounds 12-15 underline a beneficial role of both Se-and ketone moiety, whereas a presence of ester, amide or cyanate moieties as well as an absence of selenium result in total decrease of the desirable biological actions. These results in a second pair of sensitive/multidrug resistant cancer cell lines promote this series of selenocompounds (1, 9-11) as promising agents to overcome cancer multidrug resistance, giving a new therapeutic perspective. 
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